More than a year under new management, AstraZeneca Plc is focused on rebuilding its late-stage pipeline. But it will take some time before this translates into revenue and profit growth for the company as a whole. Presenting the company’s 2013 results on 6 February, Pascal Soriot, the chief executive, said that both revenue and core earnings per share will drop again this year, after declines in 2013.
